Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer: guideline recommendations.

Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer: guideline recommendations.

12th March 2010
Program in Evidence-based Care


| More

Source: National Guidelines Clearinghouse

DISEASE/CONDITION(S)
Locally advanced (nonmetastatic [stage III or IV]) or recurrent/metastatic squamous cell carcinoma of the head and neck (HNSCC)

GUIDELINE CATEGORY

  • Assessment of Therapeutic Effectiveness
  • Treatment
CLINICAL SPECIALTY
  • Physicians
INTENDED USERS
  • Physicians
GUIDELINE OBJECTIVE(S)
  • To evaluate the benefits associated with the use of anti-epidermal growth factor receptor (anti-EGFR) therapies in squamous cell carcinoma of the head and neck (HNSCC)

Keywords:
Epidermal growth factor receptor, stage III and IV head and neck cancer, recurrent/metastatic squamous cell carcinoma of the head and neck

Copyright® 2004 - 2010 Business Briefings, Ltd. All rights reserved.
Touch Oncology is for informational purposes and should not be considered medical advice, diagnosis or treatement recommendations.